HeimAVDL • NASDAQ
add
Avadel Pharmaceuticals PLC
Við síðustu lokun
7,90 $
Dagbil
7,80 $ - 8,35 $
Árabil
7,39 $ - 19,09 $
Markaðsvirði
761,26 m. USD
Meðalmagn
1,33 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 50,02 m. | 613,22% |
Rekstrarkostnaður | 44,20 m. | 5,21% |
Nettótekjur | -2,62 m. | 92,76% |
Hagnaðarhlutfall | -5,25 | 98,98% |
Hagnaður á hvern hlut | -0,03 | 92,68% |
EBITDA | 708,00 þ. | 102,05% |
Virkt skatthlutfall | -3,47% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 65,81 m. | -57,04% |
Heildareignir | 158,25 m. | -22,08% |
Heildarskuldir | 83,59 m. | -10,07% |
Eigið fé alls | 74,66 m. | — |
Útistandandi hlutabréf | 96,36 m. | — |
Eiginfjárgengi | 10,13 | — |
Arðsemi eigna | -0,52% | — |
Ávöxtun eigin fjár | -0,73% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -2,62 m. | 92,76% |
Handbært fé frá rekstri | -6,89 m. | 81,98% |
Reiðufé frá fjárfestingum | 4,93 m. | -49,80% |
Reiðufé frá fjármögnun | 1,18 m. | -96,14% |
Breyting á handbæru fé | -265,00 þ. | -114,51% |
Frjálst peningaflæði | -9,99 m. | 64,96% |
Um
Avadel Pharmaceuticals plc, is a specialty pharmaceutical company. Avadel markets products in the hospital and primary care spaces. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.
The company was founded as Flamel Technologies SA in Lyon, France in 1990.
The company acquired Éclat Pharmaceuticals of St. Louis, Missouri in March 2012.
On 8 February 2016, the company acquired FSC Holdings, LLC, which included its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.
On 3 January 2017, Flamel, Éclat, and FCS Pediatrics became Avadel Pharmaceuticals plc after the Company completed a cross-border merger from France to Ireland.
In 2019, Mike Anderson, CEO of Avadel Pharmaceuticals has resigned, and Gregory Divis, COO of the company was appointed as his temporary successor. Meanwhile, Craig Stapleton, chairman of the Dublin-headquartered Avadel, has also stepped down. That same year, the company filed for Chapter 11 bankruptcy.
In May 2023, Avadel Pharmaceuticals received FDA approval for Lumryz, an extended-release oral suspension of sodium oxybate. Wikipedia
Framkvæmdastjóri
Stofnsett
1990
Vefsvæði
Starfsfólk
154
